Penn Medicine’s Abramson Cancer Center is a world leader in cancer research, patient care, and education. Our preeminent position is reflected in our continuous designation as a Comprehensive Cancer Center by the National Cancer Institute since 1973, one of 47 such Centers in the United States.
At the Abramson Cancer Center, we are dedicated to innovative and compassionate cancer care. Our clinical program, comprised of a dedicated staff of physicians, nurse practitioners, nurses, social workers, physical therapists, nutritionists, and patient care coordinators, currently sees over 90,000 outpatient visits, over 11,800 inpatient discharges, and provides over 37,000 chemotherapy treatments, and more than 66,000 radiation treatments.
Not only are we dedicated to providing state-of-the-art cancer care, the latest forms of cancer prevention, diagnosis, and treatment are available to our patients through clinical themes that developed in the relentless pursuit to eliminate the pain and suffering from cancer.
In addition, the Abramson Cancer Center is home to the 400+ basic, translational, and clinical scientists who work relentlessly to determine the pathogenesis of cancer. Together, our faculty is committed to improving the prevention, diagnosis, and treatment of cancer.
Website: Penn Medicine Abramson Cancer Center
NePtune: A Phase 2 Study of Neoadjuvant PARP Inhibition followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 Gene Alterations
